HCMSG - Hepatitis C Mentor & Support Group, Inc.
Search
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
  • Resources
    • COVID-19
    • Harm Reduction
    • Hep C Risks
    • Hep C Facts & Stats
    • Medications and Treatments >
      • Patient Assistance Programs
    • Reading
    • Links
  • Programs/Training
    • The Circle Model >
      • THE CIRCLE Registration
      • Group and Facilitator Guide
      • Circle Sites
    • Hepatitis C Online Training
    • The Hepatitis C Education and Support Group Assistance Program
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
  • Contact Us

HEPATITIS C and the IL28B GENE

4/13/2013

1 Comment

 
 HCV PROJECT


ABOUT TAG

Hepatitis C and the IL28B Gene


April 2013


What predicts response to hepatitis C virus (HCV)
treatment?

Many things help predict the likelihood of being cured (called sustained virological response or SVR) by pegylated
interferon (PEG-IFN) and ribavirin (RBV). Making sure to take all medications as
  prescribed (called adherence) will really increase the likelihood
  of SVR.
Two of the strongest SVR predictors are virus-related: the
amount of HCV in the bloodstream (called viral load) and the
strain of HCV (called genotype). For example, HCV genotype 1 is
harder to cure with PEG-IFN and RBV than genotypes 2 and 3. Medical issues (such
as being HIV-positive, having liver damage, and being overweight) can also make
HCV harder to cure.

PEG-IFN and RBV are less effective for African
Americans and people of African ancestry than people of other races and
ethnicities. Recently, researchers have discovered that this is mainly—but not
completely—due to an inherited (genetic) factor, the
interleukin-28B (IL28B) gene.


What is the IL28B gene?

Genes are working parts of our body inherited from our parents.
They determine eye, skin, and hair color as well as blood type, height, and
race. The IL28B gene is involved in the immune response to certain viruses,
including hepatitis C. There are three IL28B subtypes (called
genotypes): CC, CT, and TT. People with the CC genotype have a
stronger immune response to HCV infection than people with the CT or TT
genotypes (called non-CC genotypes). This immune response makes
people who have a CC genotype more likely to clear HCV without treatment (called
spontaneous viral clearance), within months of becoming infected.
People who have a CC genotype are also two to three times more likely to be
cured by PEG-IFN and RBV, regardless of race or HIV
status.


Race and IL28B genotype

A person of any race or ethnicity could have any IL28B genotype,
but African Americans and people of African ancestry are less likely to have the
CC genotype than people of other races and
ethnicities.





Source: Thomas DL, Thio CL, Martin MP, et al. Genetic variation in
IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009 Oct
  8;461(7265):798–801. doi: 10.1038/nature08463.



Although people with the CC genotype are more likely to be cured
by PEG-IFN and RBV, race still influences the likelihood of being cured. SVR
rates among people with the CC genotype are lower in African Americans and
people of African ancestry than in people of other races. Researchers have not
discovered other factors to explain the difference in SVR
rates.





Adapted from Ge D, Fellay J, Thompson AJ, et al. Genetic variation in
IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep
  17;461(7262):399-401. doi: 10.1038/nature08309.


IL28B and new HCV drugs



Adding one of the new oral HCV drugs (called direct-acting
antivirals
or DAAs) to PEG-IFN and RBV or using a
combination of DAAs will increase SVR rates in people with non-CC genotypes,
regardless of race or ethnicity. It is still unclear whether IL28B genotype has
a strong influence on cure rates from DAAs without PEG-IFN, or which DAAs are
best for people with non-CC genotypes.

Regardless of your IL28B genotype,
it is important to get a viral load test 4 or 12 weeks after starting HCV
treatment, to see if it is working. People with an undetectable hepatitis C
viral load at 4 or 12 weeks are more likely to be cured, especially if they have
the IL28B CC genotype.


How can I find out my IL28B genotype?



You can take a blood test to learn your IL28B genotype (called the
IL28B genotype test). You only need to take this test once,
because your IL28B genotype never changes.


·       
IL28B genotype may determine the type—and possibly length—of your HCV
  treatment. It can be important information for treatment
decision-making.



·       
A person’s IL28B genotype should never be used to withhold HCV
treatment, since people with non-CC genotypes can also be cured.



·       
Soon, there will be more information about the best treatments for
people with non-CC genotypes. Check with your medical providers.


1 Comment
www.bestessay link
8/22/2013 02:13:00 am

Genes work regions of our own bodies inherited from each of our moms and dads. They will establish attention, epidermis, as well as curly hair shade as well as blood variety, peak, as well as
race.

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011

    Categories

    All

    RSS Feed

Privacy Policy